新型口服抗凝药达比加群酯研究进展

摘要

达比加群酯是一种新型合成的直接凝血酶抑制剂,口服经胃肠吸收后,在体内转化为具有直接抗凝血活性的达比加群.现主要对达比加群酯的药理学、相关临床研究、临床应用前景进行综述.%Dabigatran etexilate is the prodrug of dabigatran, a potent, nonpeptidic small molecule that specifically and reversibly inhibits both free and clot-bound thrombin by binding to the active site of the thrombin molecule. This review provides an overview of the pharmacology of dabigatran etexilate, and describes the most recent published data on clinical trials with the new oral anticoagulants.